These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 26519882

  • 1. Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation.
    Zhou Y, He X, Chen Y, Huang Y, Wu L, He J.
    Biochem Biophys Res Commun; ; 468(1-2):394-9. PubMed ID: 26519882
    [Abstract] [Full Text] [Related]

  • 2. Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways.
    Wang J, Fan S, Xiong Q, Niu Y, Zhang X, Qin J, Shi Y, Zhang L.
    Acta Biochim Biophys Sin (Shanghai); 2021 Aug 31; 53(9):1189-1197. PubMed ID: 34357376
    [Abstract] [Full Text] [Related]

  • 3. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway.
    Miao XY, Gu ZY, Liu P, Hu Y, Li L, Gong YP, Shu H, Liu Y, Li CL.
    Peptides; 2013 Jan 31; 39():71-9. PubMed ID: 23116613
    [Abstract] [Full Text] [Related]

  • 4. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways.
    Kang S, Chemaly ER, Hajjar RJ, Lebeche D.
    J Biol Chem; 2011 May 27; 286(21):18465-73. PubMed ID: 21478152
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake.
    Ginion A, Auquier J, Benton CR, Mouton C, Vanoverschelde JL, Hue L, Horman S, Beauloye C, Bertrand L.
    Am J Physiol Heart Circ Physiol; 2011 Aug 27; 301(2):H469-77. PubMed ID: 21602475
    [Abstract] [Full Text] [Related]

  • 6. Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the AMPK pathway.
    Xu WW, Guan MP, Zheng ZJ, Gao F, Zeng YM, Qin Y, Xue YM.
    Cell Physiol Biochem; 2014 Aug 27; 33(2):423-32. PubMed ID: 24556697
    [Abstract] [Full Text] [Related]

  • 7. The lipid peroxidation product 4-hydroxy-trans-2-nonenal causes protein synthesis in cardiac myocytes via activated mTORC1-p70S6K-RPS6 signaling.
    Calamaras TD, Lee C, Lan F, Ido Y, Siwik DA, Colucci WS.
    Free Radic Biol Med; 2015 May 27; 82():137-46. PubMed ID: 25617592
    [Abstract] [Full Text] [Related]

  • 8. MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway.
    Kuwabara Y, Horie T, Baba O, Watanabe S, Nishiga M, Usami S, Izuhara M, Nakao T, Nishino T, Otsu K, Kita T, Kimura T, Ono K.
    Circ Res; 2015 Jan 16; 116(2):279-88. PubMed ID: 25362209
    [Abstract] [Full Text] [Related]

  • 9. PAS kinase is a nutrient and energy sensor in hypothalamic areas required for the normal function of AMPK and mTOR/S6K1.
    Hurtado-Carneiro V, Roncero I, Egger SS, Wenger RH, Blazquez E, Sanz C, Alvarez E.
    Mol Neurobiol; 2014 Oct 16; 50(2):314-26. PubMed ID: 24445950
    [Abstract] [Full Text] [Related]

  • 10. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte.
    Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR.
    J Biol Chem; 2004 Jul 30; 279(31):32771-9. PubMed ID: 15159410
    [Abstract] [Full Text] [Related]

  • 11. Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway.
    Wei H, Bu R, Yang Q, Jia J, Li T, Wang Q, Chen Y.
    J Diabetes Res; 2019 Jul 30; 2019():8905917. PubMed ID: 31886288
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy.
    Li HL, Yin R, Chen D, Liu D, Wang D, Yang Q, Dong YG.
    J Cell Biochem; 2007 Apr 01; 100(5):1086-99. PubMed ID: 17266062
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A novel, de novo mutation in the PRKAG2 gene: infantile-onset phenotype and the signaling pathway involved.
    Xu Y, Gray A, Hardie DG, Uzun A, Shaw S, Padbury J, Phornphutkul C, Tseng YT.
    Am J Physiol Heart Circ Physiol; 2017 Aug 01; 313(2):H283-H292. PubMed ID: 28550180
    [Abstract] [Full Text] [Related]

  • 17. AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway.
    Meng R, Pei Z, Zhang A, Zhou Y, Cai X, Chen B, Liu G, Mai W, Wei J, Dong Y.
    Arch Biochem Biophys; 2011 Jul 01; 511(1-2):1-7. PubMed ID: 21530483
    [Abstract] [Full Text] [Related]

  • 18. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
    Tulipano G, Faggi L, Cacciamali A, Spinello M, Cocchi D, Giustina A.
    J Neuroendocrinol; 2015 Jan 01; 27(1):20-32. PubMed ID: 25323047
    [Abstract] [Full Text] [Related]

  • 19. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
    Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T.
    Breast Cancer Res Treat; 2012 Apr 01; 132(2):449-61. PubMed ID: 21638053
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.